He is a seasoned business leader with a successful track record of over 26 years across local and area roles within the pharmaceutical industry
The company is bringing precision therapies for gynaecological cancers
The performance was below anticipated levels, primarily due to external factors such as seasonal disruption that affected overall results
The Board of Directors of the company recommends a final dividend of Rs. 42 per equity share for the 12 months period ended March 31, 2025
The Pediatric vaccine portfolio delivered double-digit growth and maintained its market leadership in the private market
Strong topline growth driven by solid performance across key brands.
The company is committed to a new category development in areas like adult Immunization with products like Shingrix to make a positive impact to the lives of the patients in India
General Medicine grows 5% and Vaccines 10% led by Shingrix
Time to combine innovation, access and technology to deliver positive patient outcomes
Subscribe To Our Newsletter & Stay Updated
